U.S. President Donald Trump heads to Pittsburgh, Pennsylvania on Friday to headline a rally to celebrate Nippon Steel's ...

Gilead's twice-yearly HIV injection faces headwinds from US aid pullback. Thank you for reading Nation.Africa Show plans Gilead Sciences says it still plans to supply its twice-yearly injection for ...

Shares of Gilead Sciences, Inc. (GILD) were in the spotlight on Friday morning after the company reportedly said that it ...

Arguably the most notable of the FDA’s upcoming decisions is that regarding Gilead’s twice-yearly HIV prophylaxis lenacapavir ...

The Trump administration has moved to end funding for a broad swath of HIV vaccine research, saying current approaches are ...

The administration of Donald Trump has reportedly terminated funding for several HIV vaccine research programs.

At current levels, we recommend prospective investors to opt for GSK as compared to GILD on the back of a strong and wide ...

Gilead Sciences is paying $10 million for sole ownership of arenavirus immunotherapies for hepatitis B (HBV) and HIV ...

Gilead Sciences is well-positioned to continue to strengthen its position as a leader in the HIV therapy market. Learn more ...

You can reach Jason on Signal at JasonMast.05. Gilead said Tuesday that it will soon begin Phase 3 testing for a drug it believes could prevent HIV infection with just a single shot every year.

Gilead Sciences says it still plans to supply its twice-yearly injection for preventing HIV infection in low-income countries if it wins U.S. approval despite funding uncertainty over the Trump ...